Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Blood (2023) 142 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2023-180141

Published: 2023

Journal Articles

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown

Blood (2021) 138 (1): 44–56.

https://doi.org/10.1182/blood.2020006765

Published: 2021

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

William Blum, MD, Rebecca B. Klisovic, MD, Amy Johnson, PhD, Cheryl Kefauver, RN, Mitch Phelps, PhD, David Lucas, PhD, Lenguyen Huynh, Shujun Liu, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Guido Marcucci, MD, John C. Byrd, MD

Blood (2007) 110 (11): 890.

https://doi.org/10.1182/blood.V110.11.890.890

Published: 2007

Journal Articles

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

William Blum, MD, Rebecca B. Klisovic, MD, Cheryl Kefauver, RN, Amy Johnson, PHD, Mitch Phelps, James T. Dalton, David Lucas, PHD, LeNguyen Huynh, Shujun Liu, Michael R. Grever, MD, A.D. Colevas, Guido Marcucci, MD, John C. Byrd, MD

Blood (2006) 108 (11): 4578.

https://doi.org/10.1182/blood.V108.11.4578.4578

Published: 2006

Journal Articles

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

Shuhong Zhang, PhD, Valerie L. White, Amy Johnson, PhD, Ching-Shih Chen, PhD, Sherif S. Farag, MD, PhD

Blood (2006) 108 (11): 5075.

https://doi.org/10.1182/blood.V108.11.5075.5075

Published: 2006

Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD

Blood (2004) 104 (11): 3471.

https://doi.org/10.1182/blood.V104.11.3471.3471

Published: 2004

NARROW

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Email alerts

ASH Publications

American Society of Hematology

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only